TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10027428

Group type: EXPERIMENTAL
Intervention: Spiros Inhalation System (Dura Pharmaceuticals; 108 microg/actuation of albuterol sulfate equivalent to 90 microg of albuterol base)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: albuterol metered-dose inhaler (MDI; 90 microg/actuation of albuterol)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study: 8622105

Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg once daily (n = 15)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Isepamicin 8 mg/kg once daily (n = 93)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily (n = 18)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily (n = 47)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 203

Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 203
Study: 2045762

Group type: EXPERIMENTAL
Intervention: Felodipine ER, 10 mg once daily for 2 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ), 25 mg once daily for 2 weeks
Number of subjects: 28
Study: 6168511

Group type: EXPERIMENTAL
Intervention: Synthetic secretin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Natural secretin
Number of subjects: 12
Study: 31910850

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 340

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 340
Study: 31117800

Group type: EXPERIMENTAL
Intervention: Conscious sedation with midazolam and fentanyl
Number of subjects: 5328

Group type: COMPARATOR
Intervention: No sedation (Control)
Number of subjects: 5328
Study: 28024090

Group type: EXPERIMENTAL
Intervention: 4 Pillars Practice Transformation Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study: 25158273

Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 142

Group type: COMPARATOR
Intervention: Enuretic alarm
Number of subjects: 142
Study: 23313581

Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (AVP) 20 IU
Number of subjects: 2

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 2
Study: 22021025

Group type: EXPERIMENTAL
Intervention: VA MEDIC‐E intervention (pharmacist-led shared medical appointments program)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Standard primary care (control)
Number of subjects: 99
Study: 19307466

Group type: EXPERIMENTAL
Intervention: Lisinopril/spironolactone (40 mg lisinopril/25 mg spironolactone)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 17589899

Group type: EXPERIMENTAL
Intervention: Body awareness therapy (2 hours weekly for 24 weeks)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Body awareness therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Apparently healthy persons (control group)
Number of subjects: 21
Study: 15217837

Group type: EXPERIMENTAL
Intervention: High AF1q expression (top tertile)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Low AF1q expression (lower 2 tertiles)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Increasing AF1q expression level
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High AF1q expression
Number of subjects: 64
Study: 11120401

Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions related to pharmacotherapy treatment adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacologic measures of medication adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment adherence interventions scale ratings
Number of subjects: 0
Study: 9512836

Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 3854
Study: 9691876

Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation via a laryngeal mask airway
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spontaneous breathing via a laryngeal mask airway
Number of subjects: 40
Study: 1926651

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (Monuril), 3-gram single dose
Number of subjects: 63

Group type: COMPARATOR
Intervention: Norfloxacin (Noroxine), 400 mg twice daily for 5 days
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (Monuril)
Number of subjects: 63
Study: 6310053

Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31956037

Group type: EXPERIMENTAL
Intervention: Intensified platinum-based chemotherapy
Number of subjects: 248

Group type: COMPARATOR
Intervention: Conventional anthracycline-based chemotherapy
Number of subjects: 248
Study: 31291055

Group type: EXPERIMENTAL
Intervention: Initial mild to moderate daily GER
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Persistent and aggravated GER
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GER new-onset rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GER disappearance rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GER prevalence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GER persistence vs aggravation
Number of subjects: 0
Study: 27718176

Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 201

Group type: COMPARATOR
Intervention: LSG
Number of subjects: 201
Study: 27078989

Group type: EXPERIMENTAL
Intervention: Shenyi Capsule + Modified Yiqi Chutan Recipe (MYCR) + chemotherapy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Shenyi Capsule + MYCR + chemotherapy
Number of subjects: 80
Study: 24262291

Group type: EXPERIMENTAL
Intervention: High-fat overfeeding for 5 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Insulin-stimulation after high-fat overfeeding
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Number of subjects: 45
Study: 22128078

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every two weeks for 12 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 21156950

Group type: EXPERIMENTAL
Intervention: Protective ventilatory strategy (tidal volumes of 6‐8 mL/kg, PEEP of 8‐10 cm H(2)O)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional ventilatory strategy (tidal volumes of 10‐12 mL/kg, PEEP of 3‐5 cm H(2)O)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Protective ventilatory strategy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional ventilatory strategy
Number of subjects: 118
Study: 17627007

Group type: EXPERIMENTAL
Intervention: Sun protection habits (varied by sex)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: Latent class analysis (LCA)
Number of subjects: 725
Study: 16330984

Group type: EXPERIMENTAL
Intervention: Warfarin therapy for 6 weeks after negative venograms
Number of subjects: 1972

Group type: COMPARATOR
Intervention: No further anticoagulation after negative venograms
Number of subjects: 1972

Group type: EXPERIMENTAL
Intervention: Clinical pathway including continuous epidural anesthesia
Number of subjects: 1972
Study: 11996271

Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate (PC) reinfusion (9 to 20 U, 13.0 ± 5.4 U, 0.42 ± 0.22 U/kg) after open heart surgery.
Number of subjects: 16
Study: 9080886

Group type: EXPERIMENTAL
Intervention: mefloquine
Number of subjects: 23

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study: 8442598

Group type: EXPERIMENTAL
Intervention: Active NCPAP (7.5 cm H2O)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo NCPAP (< 1.5 cm H2O)
Number of subjects: 8
Study: 3533272

Group type: EXPERIMENTAL
Intervention: Tizanidine (maximum daily dose 18 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbamazepine (maximum daily dose 900 mg)
Number of subjects: 12
Study: 30192751

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 112
Study: 27460905

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 573
Study: 24775575

Group type: EXPERIMENTAL
Intervention: 200 units of onabotulinumtoxinA
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 22617934

Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 20

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Junior trainees
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Senior trainees
Number of subjects: 20
Study: 20437555

Group type: EXPERIMENTAL
Intervention: Standardized stroke discharge orders
Number of subjects: 3361

Group type: COMPARATOR
Intervention: Usual care (non-intervention hospitals)
Number of subjects: 3361
Study: 18561584

Group type: EXPERIMENTAL
Intervention: Once-daily azelaic acid 15% gel
Number of subjects: 72

Group type: COMPARATOR
Intervention: Twice-daily azelaic acid 15% gel
Number of subjects: 72
Study: 15716474

Group type: EXPERIMENTAL
Intervention: Older subjects (ages 15-19)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Younger subjects (ages 8-14)
Number of subjects: 0
Study: 12209299

Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Lichtenstein patch
Number of subjects: 206
Study: 10685300

Group type: EXPERIMENTAL
Intervention: Telephone group (n = 30)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard group (n = 32)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Abnormal pneumocardiogram
Number of subjects: 65

Group type: COMPARATOR
Intervention: Normal pneumocardiogram
Number of subjects: 65
Study: 8685201

Group type: EXPERIMENTAL
Intervention: Tianeptine 37.5 mg/day
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Tianeptine 25 mg/day
Number of subjects: 315

Group type: COMPARATOR
Intervention: Mianserin 30 mg/day
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Tianeptine 37.5 mg
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Overall assessment by patient and investigator
Number of subjects: 315
Study: 1524161

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 100 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 300 mg daily
Number of subjects: 0
Study: 6741676

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 50
Study: 30607570

Group type: EXPERIMENTAL
Intervention: Ial System Duo
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Belotero Basic/Balance
Number of subjects: 59
Study: 30552263

Group type: EXPERIMENTAL
Intervention: Supervised, progressive treadmill walking exercise training three times per week for a 3-month period.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Supervised, progressive low-intensity resistive exercise three times per week for a 3-month period.
Number of subjects: 40
Study: 27189616

Group type: EXPERIMENTAL
Intervention: Partly supervised exercise intervention (endurance and resistance exercise)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 153
Study: 24686107

Group type: EXPERIMENTAL
Intervention: Glucose-insulin-potassium (GIK) administered in ambulances
Number of subjects: 2079
Study: 22831888

Group type: EXPERIMENTAL
Intervention: Aprepitant alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aprepitant with scopolamine
Number of subjects: 120
Study: 20048611

Group type: EXPERIMENTAL
Intervention: 3M Steri-Strip S Surgical Skin Closure
Number of subjects: 51
Study: 17279852

Group type: EXPERIMENTAL
Intervention: Glucose drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial acts of self-control
Number of subjects: 0
Study: 16216096

Group type: EXPERIMENTAL
Intervention: Cervitec varnish applied at 3-month intervals (CHX group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no treatment, group C)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Cervitec varnish (CHX group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 200
Study: 12011122

Group type: EXPERIMENTAL
Intervention: (90)Y ibritumomab tiuxetan 0.4 mCi/kg (n = 73)
Number of subjects: 143

Group type: COMPARATOR
Intervention: rituximab 375 mg/m2 IV weekly for four doses (n = 70)
Number of subjects: 143
Study: 9892509

Group type: EXPERIMENTAL
Intervention: Intra-arterial prostaglandin E1 (10 microg i.a. over 30 min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (15 microg i.v. over 30 min)
Number of subjects: 30
Study: 7619644

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral skills training program focused on sexual assertiveness skills and reduction of risk-related behaviors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education-only program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral skills training program
Number of subjects: 0
Study: 2551907

Group type: EXPERIMENTAL
Intervention: Intravenous polymyxin B during the first week after burn injury
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Perioperative polymyxin B given in conjunction with an excisional procedure of the burn wound
Number of subjects: 2
Study: 61952

Group type: EXPERIMENTAL
Intervention: FZ. 560 (combination of fentonium bromide 10 mg, dehydrocholic acid 25 mg, pancreatin 50 mg, lactulose 200 mg)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fentonium bromide 10 mg (control group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Other components (control group)
Number of subjects: 37
Study: 31018678

Group type: EXPERIMENTAL
Intervention: Intervention in stepped-wedge trials with more than two levels of clustering
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard and non-standard designs for stepped-wedge trials
Number of subjects: 0
Study: 29084409

Group type: EXPERIMENTAL
Intervention: HX575 (biosimilar epoetin alfa)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Epoetin alfa (reference medicine)
Number of subjects: 49
Study: 26416999

Group type: EXPERIMENTAL
Intervention: Epirubicin plus cyclophosphamide followed by docetaxel (EC-T; 90 mg/m2 epirubicin, 600 mg/m2 cyclophosphamide, 100 mg/m2 docetaxel)
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Epirubicin plus docetaxel followed by capecitabine (ET-X; 90 mg/m2 epirubicin, 75 mg/m2 docetaxel, 1250 mg/m2 capecitabine)
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Epirubicin plus cyclophosphamide followed by docetaxel (EC-T)
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Epirubicin plus docetaxel followed by capecitabine (ET-X)
Number of subjects: 1384
Study: 22193920

Group type: EXPERIMENTAL
Intervention: Vigorous-intensity LTPA (>2,000 kcal/week)
Number of subjects: 19003

Group type: EXPERIMENTAL
Intervention: Total LTPA (>3,000 kcal/week)
Number of subjects: 19003

Group type: EXPERIMENTAL
Intervention: Vigorous intensity activities (>50% of total LTPA)
Number of subjects: 19003
Study: 20393362

Group type: EXPERIMENTAL
Intervention: MM + acamprosate
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: MM + naltrexone
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: MM + acamprosate + naltrexone
Number of subjects: 786

Group type: EXPERIMENTAL
Intervention: MM + acamprosate + combined behavioral intervention
Number of subjects: 786

Group type: COMPARATOR
Intervention: Medical management + placebo (MM + placebo)
Number of subjects: 786
Study: 18521462

Group type: EXPERIMENTAL
Intervention: Desflurane 2.5%
Number of subjects: 102

Group type: COMPARATOR
Intervention: Sevoflurane 1.5% combined with 50% nitrous oxide and oxygen
Number of subjects: 102
Study: 15986587

Group type: EXPERIMENTAL
Intervention: Olfactory function testing using the 'Sniffin' Sticks' technique
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ability to identify odors
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Psychometric function tests
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Serum levels of bilirubin and zinc
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Etiology of CL (e.g., alcoholism)
Number of subjects: 45
Study: 12701670

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication and placebo (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analytical psychotherapy (control group)
Number of subjects: 0
Study: 10499654

Group type: EXPERIMENTAL
Intervention: Leucocyte-depleted cardioplegia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Blood cardioplegia without leucocyte depletion
Number of subjects: 40
Study: 7569495

Group type: EXPERIMENTAL
Intervention: Robust Bayesian methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 1952204

Group type: EXPERIMENTAL
Intervention: Epidural fentanyl infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous fentanyl infusion
Number of subjects: 40
Study: 7019930

Group type: EXPERIMENTAL
Intervention: 200 mg tiaprofenic acid given 3-times daily for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: 600 mg aspirin given 3-times daily for 7 days
Number of subjects: 50
Study: 29040445

Group type: EXPERIMENTAL
Intervention: 60 mg b.i.d. ticagrelor
Number of subjects: 50

Group type: COMPARATOR
Intervention: 90 mg b.i.d. ticagrelor
Number of subjects: 50
Study: 26395889

Group type: EXPERIMENTAL
Intervention: Topiramate (100 or 200 mg)
Number of subjects: 0
Study: 25516879

Group type: EXPERIMENTAL
Intervention: Silorane-based composite resin (P90 System Adhesive Self‐Etch Primer and Bond and Filtek P90 Low Shrink Posterior Restorative)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Dimethacrylate-based composite (Adper SE Plus and Filtek P60 Posterior Restorative)
Number of subjects: 100
Study: 22369102

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 927

Group type: COMPARATOR
Intervention: Non-randomized youth (control)
Number of subjects: 927
Study: 20113303

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behaviour Therapy (CBT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Group Psychoeducation (PE)
Number of subjects: 88
Study: 18971408

Group type: EXPERIMENTAL
Intervention: Consumer-providers (CPs)
Number of subjects: 93
Study: 16159631

Group type: EXPERIMENTAL
Intervention: Recombinant grass pollen allergens
Number of subjects: 0
Study: 14741088

Group type: EXPERIMENTAL
Intervention: Volume control (VC)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Pressure control (PC)
Number of subjects: 114
Study: 10551575

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine (diluted with NaCl 0.9%)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine (diluted with NaCl 10.9% and glucose 30%)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90
Study: 8673548

Group type: EXPERIMENTAL
Intervention: Chinese herbal treatment (31 Chinese herbs), 28 tablets each day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (cellulose placebo), 28 tablets each day
Number of subjects: 30
Study: 1890532

Group type: EXPERIMENTAL
Intervention: 1.25% AmF gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.125% AmF toothpaste
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.4% F gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0% F gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups during 6-month discontinuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AmF-treated groups
Number of subjects: 0
Study: 6311009

Group type: EXPERIMENTAL
Intervention: Amdinocillin
Number of subjects: 299

Group type: COMPARATOR
Intervention: Tobramycin or other comparative agents
Number of subjects: 299

Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 299
Study: 30536970

Group type: EXPERIMENTAL
Intervention: Polyhexanide
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Saline
Number of subjects: 85

Group type: COMPARATOR
Intervention: Cold argon plasma
Number of subjects: 85
Study: 29342199

Group type: EXPERIMENTAL
Intervention: Low dose metformin (375 mg followed by 250 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High dose metformin (1000 mg followed by 1000 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both doses of metformin
Number of subjects: 20
Study: 26774115

Group type: EXPERIMENTAL
Intervention: Vitamin B12 (500 μg) and folic acid (400 μg)
Number of subjects: 2919
Study: 24815501

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CT angiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interhospital transfers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular treatment in the same center
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trial progression
Number of subjects: 0
Study: 21971437

Group type: EXPERIMENTAL
Intervention: Perineural Tramadol (Group TPN)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intramuscular Tramadol (Group TIM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (Group P)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Group TPN vs Group TIM
Number of subjects: 120
Study: 20646181

Group type: EXPERIMENTAL
Intervention: Flibanserin (50mg bid)
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Flibanserin (50-100mg bid)
Number of subjects: 892

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 892

Group type: COMPARATOR
Intervention: Fluoxetine (20mg qd)
Number of subjects: 892

Group type: COMPARATOR
Intervention: Paroxetine (20-40mg qd)
Number of subjects: 892
Study: 17565489

Group type: EXPERIMENTAL
Intervention: 4 mg rosiglitazone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 16485509

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention (not specified in detail)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Medications (antiparkinsonian drugs)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Normal participants (control group)
Number of subjects: 11